Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: semaxanib, sorafenib, xl-820 +35 | 1.00 |
| trials ClinicalTrials.gov | 32 Parkinson's trials, 1 stopped | 0.97 |
| literature PubMed | 265 Parkinson's papers of 97,349 | 0.27 |
| pathways Reactome | 22 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 11427
Sealed predictions
- KIT in dopamine neurons, braak+0.12 (p 0.749) → +0.24 (p 0.529)receipt 11433
Swarm cases
receipt 11433: KIT in dopamine neurons, braak
- power
- full sample +0.10 (p 0.683, n 18), 95% CI -0.38 to +0.54. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.08 (p 0.741, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.14 (p 0.567, n 18). could be the mix.
- skeptic
- leave-one-out range +0.00 to +0.23, sign flips 0; without severely affected donors +0.10 (p 0.683, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KIT in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts